Načítá se...
Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following molecular profiling has dramatically changed the way advanced adenocarcinoma is treated. However, tumor cells inevitably acquire resistance to such therapies, circumventing any sustained clinical benefit. A...
Uloženo v:
| Vydáno v: | J Mol Med (Berl) |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5696571/ https://ncbi.nlm.nih.gov/pubmed/24852181 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00109-014-1165-y |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|